ReeWire ventures

PsyMed Ventures is an early-stage venture fund investing in frontier mental health technologies. Our mission is to provide capital and support to companies that align healing, responsibility, and profitability. PsyMed’s focus areas include psychedelic medicine, neurotechnology, and precision psychiatry.

Navigare Ventures is an early-stage investor specialized in science-driven companies. Through our investments, we strengthen the industrial and societal impact of research, as well as the long-term financial capacity of our owners, Wallenberg Investments AB. Our core investment themes within deep tech are underpinned by our knowledge and network in a number of scientific fields and industries. These include advanced computing and quantum technologies, synthetic biology and bio innovation, advanced materials and nano technology as well as data-driven life science. We are long term investors - Seed and Series A and beyond - and form deep and lasting partnerships with founders and entrepreneurs. Our extensive industrial and scientific networks gives us the opportunity to provide capital, network, and know-how to transform promising science start-ups into successful companies. Who we are Navigare Ventures, based in Stockholm, is a fully owned subsidiary of Wallenberg Investments AB. We are a team of scientists, industrialists and entrepreneurs who understand the challenges of turning cutting-edge technologies to successful ventures. As part of the Wallenberg ecosystem, our returns fuel the next generation of scientific advancement through research funding from the Wallenberg Foundations to Swedish universities. What we are looking for We partner with experienced entrepreneurial teams that combine scientific excellence with strong business acumen. In this respect, your company should have a unique offering based on a profound understanding of your scientific or technological field and its market and industrial environment. You should also be capable of demonstrating the viability and commercial potential of your product by engaging with real customers. You are raising capital to scale the R&D, production, marketing, and sales capabilities of your company. Our investment philosophy We only invest in companies we understand. While this is an important general principle in any investment activity, it is even more important when making early-stage investments in new technology. If we don’t understand your science, we won’t understand what experts tell us about the value chain and how it works, or what the competitive landscape looks like. And most importantly, we won’t be able to help you develop your strategy and navigate through the challenges of deep-tech start-ups. So, when preparing a meeting with us, don’t put too much emphasis on future revenue projections. That’s important too, in due time. But first, be prepared for long sessions in front of a whiteboard, explaining to us how your material, algorithm, or antibody functions. We don’t need to understand all the equations, but we need to get the heuristics. We are scientists at heart, eager to learn, and we carry a deep conviction that the world is fundamentally understandable. Core investment themesAdvanced computing and quantum technologies: Digitization and automation deepens in industry and society, driven by breakthroughs in computing and AI. Our focus includes improving existing technologies as well as finding completely new platforms in AI and other areas of applied mathematics as well as in novel computer architectures, communication technology, hardware and design. Synthetic biology and bio innovation: Synthetic biology and bio innovations contribute to a more sustainable society. Companies in this field often combine principles of biology, engineering, and computer science for the development of new biological products and manufacturing methods. Advanced materials and nano technology: New materials and nanoscale technology enable disruptions with the potential to benefit numerous existing industries. From quantum materials to biomaterials and biologically inspired nanostructures, we look for the most promising technology platforms in the field. Data-driven life science: Combining digital technology and data with life science drives scientific understanding and enables novel products. Our focus is on data-driven methods to increase personalization and precision of medical interventions, accelerate product development, digitalize care among other advancements.

Amgen Ventures has made >70 INVESTMENTS placing >$400M of the $625M Amgen has committed to support healthcare innovation and interconnectivity at all stages. Amgen Ventures offers us a unique conduit to identify and support key innovators in healthcare at early stages of translational sciences by providing investment capital and access to Amgen’s vast experience in developing leading drugs. AREAS OF INVESTMENTTHERAPEUTICS: Identify promising pipeline assets in Amgen’s therapeutic areas: oncology, immune- oncology, cardiovascular, inflammation, bone health, nephrology, metabolic disorders, and neuroscience. DRUG DISCOVERY & EMERGING TECHNOLOGIES: Improve the discovery process with new technologies including cell therapies, gene-editing and gene-therapies, regenerative medicine, and drug delivery. DIGITAL HEALTHCARE SERVICES, INFORMATION & ANALYTICS: Enhance Amgen medicines by improving real world outcomes and delivering greater value to healthcare systems, doctors, and patients.

SeaX Ventures is a venture capital fund investing globally in early-stage companies with groundbreaking “exponential” technologies. We support visionary entrepreneurs across the world on their journeys to build great companies. We invest everywhere In the U.S. In Southeast Asia. Everywhere that founders are working on great ideas, we’ll be there. Centered on South East Asia expansion Our LPs consist of a few of the largest corporations in the region. We work with them strategically by making connections to the innovative entrepreneurs in whose startups we invest. That way, both our portfolio companies and our corporate partners benefit. Our unique 3As approachAccess: We provide our LPs access to deal flow globally with a focus on the U.S. and Asia. Accelerate: We leverage the platforms and networks of our sister company (RISE) which has over 2000+ startup alumni across the U.S. and Asia and several hundred corporate partners. Advantage: Our LPs are top multinational corporations and family offices. Collectively, we are a network of entrepreneurs, business partners, and co-investors. Bridging Silicon Valley and Asia Our knowledge of markets in both the US and Asia empowers us to identify and assist founders building audacious companies. Our focus is deep-tech We focus on exponential technologies that can transform societies and help countries achieve high levels of economic progress. So far, we’ve invested in Web3, biotech, advanced materials, and AI but we are certainly not limited to those areas. We’re also looking to support groundbreaking companies in agriculture, space, robotics, and more. Healthcare / Biotech Web3 / Crypto Material Science / Nanotechnology Artificial Intelligence Hardware / Robotics Foodtech

We build and invest in companies that positively impact human health with smart solutions, breakthrough science and technology. Our focus is on innovation in digital healthcare, connected medical devices, and life sciences We focus on therapeutic and preventive technology solutions addressing unmet needs in some of the most vulnerable segments of society: women, children and the elderly. Digital transformation will continue to shape our lives and has the potential to transform care. We aim to build and support Digital Health & Life Sciences companies working to make healthcare smarter, using data to improve care and outcomes, and reinventing the patient journey. Our vision for the future of healthcare guides our investment strategy. A data driven digital transformation will shape the future of healthcare. The traditional biopharma model will evolve into an integrated model, where prevention, precision cure, and care management will coexist in a highly personalized patient-centric solution. Our goal is to support the creation of life transforming care products and therapies. We believe the future of healthcare lies in supporting the next-generation of founders and teams who will lead us there. What do we look for?Innovation and groundbreaking opportunities in our sectors of focus: digital health, life sciences, tech-enabled care delivery, and connected devices Innovative treatments for Central Nervous System (CNS) disorders, in particular neurodevelopmental disorders, mental health and epilepsy Founders and teams with domain expertise who seek collaborative investment partners Investments that span development and commercial phases, with a focus on early stage opportunities (Pre-Seed to Series A). Our investment approachOur investment approach combines direct investments in early-stage companies with venture creation from bold ideas in global innovation hubs Our goal is to enable talented entrepreneurs to scale more quickly and effectively through access to our capital, enterprise capabilities and consumer touchpoints, while offering expertise and insights from Angelini’s unique perspective. We invest primarily across Europe, North America and Israel, recognizing that healthcare technology innovation is occurring in many cities around the world. We have committed €300M for investments and company creation in digital health and life sciences. What do we commit to you?Active and involved healthcare investors who operate with integrity, approachability, and transparency A team of passionate healthcare and venture capital experts diverse in demographic and experience A track record of success and experience navigating the ups and downs of early-stage company building Access to a world-class advisory board to leverage C-level experience, expertise, and leadership in healthcare

2048 Ventures is a thesis-driven earliest stage venture capital firm. We are founders, experienced operators, nerds and dreamers obsessed with the future. We've backed over 200 startups and have the experience and conviction to lead your pre-seed. We get you and your vision before others We are systems thinkers, engineers, and product junkies. We think about the future non-stop and are ready to understand and back you before anyone else. When we decide to invest, we write you a check and then help you close the rest of the round. If you are a mission-driven team, with strong founder market-fit and a vision for what the future should look like, then we would love to meet you. We love serial founders, but we are also very excited about being the first to believe in underdogs, immigrants, and diverse founders who are going on their first founder journey. We are not your typical pre-seed firm We are a thesis-driven investor and invest in next generation platforms - APIs, data, infrastructure, marketplaces, and specific types of vertical SaaS. We invest across verticals, but spend most of our time thinking about: biotechnology, digital health, AI/ML, Robotics, AR/VR, Blockchain, Security, Energy, Mobility, Logistics, Fintech, Marketplaces, Productivity, Culture, and Communities. We don't care where you are based and we are happy to lead your pre-seed anywhere in North America. We've invested across 20+ cities including NYC, LA, Boston, Toronto, Austin, Denver, Seattle, Montreal, Atlanta, Detroit, Chicago, Philadelphia, and Minneapolis. Who we are We are a team of experienced operators and dreamers who are passionate about working with founders at the earliest stage. Collectively, we have invested in over 200 early stage startups. We are proud to have an NPS score of 100 from our founders.